Webcast
Ensuring Sponsor and Site ROI from Portal Implementation
To view the media player you will need Adobe Flash!
Download Adobe Flash
Download Adobe Flash
The video player is loading...
The return on investment from using a clinical trial portal to manage document exchange and communication with investigative sites versus using traditional paper-based methods is clear. From reducing study start-up cycle time to expediting document distribution and management during conduct and close-out, the time and money savings are measurable. In addition, there are added benefits of security and control that come with using a portal that contribute to ROI. However, most of the time, clinical trial portal ROI models are built only from the sponsor perspective, leaving investigative sites questioning, “What’s in it for me? This is just one more system I have to deal with!” To effectively implement a clinical trial portal, investigator site acceptance, adoption and use is critical. To get investigative sites on board, sponsors need to demonstrate how a portal is going to save them time and make their clinical trial participation easier, not harder. In addition to reviewing the sponsor ROI model, this session provides a practical overview of clinical trial portal requirements necessary to ensure site adoption and demonstrate ROI to sites.
- The importance of site acceptance, adoption and use of a portal
- Conveying the value of a portal to sites
- ROI from use of a portal for both sponsors and sites
More Webcasts
Live Webcast Replay: Reduce Deal Process Time and Risks with IntraLinks Designer
If you're working on a deal, you know it's like a race. But quality and accuracy are critical components if you want to quickly take advantage of deal opportunities.
IntraLinks has a way for you to better manage the entire deal process while simultaneously reducing your risk of costly mistakes and missteps. In fact, IntraLinks Designer (formerly Workspace Builder) provides the most efficient way to upload, organize and manage information throughout the life of your deal.
Podcast: M&A in 2010: Preparing for the Upturn
What does 2010 have in store for dealmakers?
Is there light at the end of the tunnel? Whilst the financial crisis caused a significant drop in deal activity in the first half of the year, the second half saw a marked improvement. In particular, private equity firms, initially shell shocked by the near collapse of the global financial crisis and the freezing of the credit markets, rallied and were engaged in deals by the end of 2009. Key questions for 2010 are: will recovery continue and how strong will recovery be?
Hedge Fund Podcast: Investor Transparency
Episode 2: “Investor Transparency: The MFA guidelines and Selective Disclosure”
Kelli Moll, partner, Schulte, Roth & Zabel LLP, discusses the MFA guidelines for establishing greater transparency between investors and fund managers and how to address the issue of selective disclosure.
Hedge Fund Podcast: Understanding US and EU Proposed Legislation
Episode 1: “What you need to know about U.S. and EU Proposed Legislation: New Regulation Requirements and Assessing Systemic Risk”
Listen to Kelli Moll, partner, Schulte Roth & Zabel LLP discuss the proposed hedge fund regulations and their approach to systemic risk.
The Journey Toward Paperless Clinical Trials
Pharma companies are seeking to bolster pipelines and cut costs more than ever before in preparation for looming patent expirations of blockbuster drugs. In this environment global collaborations are increasing while budgets are shrinking, and as a result Internet-based communication has taken a prominent position in clinical development.